To the full analysis
Clínica Baviera stock: growth
CBAV.MCClínica Baviera reported $334.41M in revenue for fiscal 2025, up 14.9% on the prior year, up 19.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
8.5%
per year from 2006 to 2025, per share 8.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
8.4%
per year from 2006 to 2025, per share 8.3%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 19.7% | 13.4% | 8.5% |
| Revenue per share | 19.2% | 13.2% | 8.4% |
| Earnings | 24.7% | 24.0% | no data |
| Earnings per share | 25.1% | 24.2% | no data |
| Free cash flow | 14.5% | 24.7% | 8.4% |
| Free cash flow per share | 14.0% | 24.4% | 8.3% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $70.39M | −$29.13M | $11.15M |
| 2007 | $86.85M | −$26.22M | $8.81M |
| 2008 | $97.44M | $7.77M | $4.65M |
| 2009 | $92.13M | $2.06M | $6.15M |
| 2010 | $99.38M | $5.81M | $10.1M |
| 2011 | $103.71M | $5.99M | $7.88M |
| 2012 | $99.6M | −$97.06K | $3.18M |
| 2013 | $88.62M | $5.41M | $7.12M |
| 2014 | $91.55M | $4.49M | $6.13M |
| 2015 | $94.77M | $5.41M | $5.67M |
| 2016 | $101.47M | $8.77M | $7.68M |
| 2017 | $110.68M | $10.83M | $7.68M |
| 2018 | $121.11M | $13.1M | $8.21M |
| 2019 | $137.77M | $14.18M | $17.96M |
| 2020 | $135.88M | $15.45M | $26.19M |
| 2021 | $191.4M | $30.35M | $40.2M |
| 2022 | $219.9M | $32.71M | $43.6M |
| 2023 | $249.24M | $39.86M | $38.93M |
| 2024 | $291.04M | $44.55M | $40.17M |
| 2025 | $334.41M | $46.61M | $51.5M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Dec 2020)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.